News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
732,869 Results
Type
Article (41462)
Company Profile (264)
Press Release (691130)
Multimedia
Podcasts (94)
Webinars (20)
Section
Business (204957)
Career Advice (2033)
Deals (35611)
Drug Delivery (132)
Drug Development (81641)
Employer Resources (173)
FDA (16524)
Job Trends (14993)
News (347073)
Policy (32760)
Tag
2027 BioCapital Elite (1)
2027 BioMidwest Elite (1)
2027 Bio NC Standard (1)
2027 Biotech Bay Elite (1)
2027 Biotech Bay Standard (3)
2027 Biotech Beach Elite (1)
2027 Genetown Elite (3)
2027 Genetown Standard (2)
2027 Pharm Country Elite (2)
2027 Pharm Country Standard (5)
Academia (2606)
Accelerated approval (53)
Adcomms (27)
Allergies (177)
Alliances (49616)
ALS (218)
Alzheimer's disease (1810)
Antibody-drug conjugate (ADC) (488)
Approvals (16943)
Artificial intelligence (688)
Autoimmune disease (315)
Automation (58)
Bankruptcy (362)
Best Places to Work (11636)
BIOSECURE Act (20)
Biosimilars (227)
Biotechnology (171)
Bladder cancer (200)
Brain cancer (74)
Breast cancer (783)
Cancer (6095)
Cardiovascular disease (485)
Career advice (1728)
Career pathing (44)
CAR-T (345)
CDC (57)
Celiac Disease (3)
Cell therapy (932)
Cervical cancer (51)
Clinical research (71228)
Collaboration (2119)
Company closure (5)
Compensation (1437)
Complete response letters (83)
COVID-19 (2749)
CRISPR (111)
C-suite (1169)
Cystic fibrosis (154)
Data (8306)
Decentralized trials (3)
Denatured (28)
Depression (164)
Dermatology (93)
Diabetes (613)
Diagnostics (6985)
Digital health (58)
Diversity (12)
Diversity, equity & inclusion (45)
Drug discovery (332)
Drug pricing (201)
Drug shortages (31)
Duchenne muscular dystrophy (292)
Earnings (92179)
Editorial (66)
Employer branding (21)
Employer resources (152)
Events (120220)
Executive appointments (1097)
FDA (20363)
Fibrodysplasia Ossificans Progressiva (8)
Friedreich's ataxia (18)
Frontotemporal dementia (35)
Funding (1772)
Gene editing (238)
Generative AI (58)
Gene therapy (733)
GLP-1 (1063)
Government (4741)
Grass and pollen (7)
Guidances (414)
Healthcare (19123)
HIV (82)
Huntington's disease (57)
IgA nephropathy (106)
Immunology and inflammation (291)
Immuno-oncology (100)
Indications (200)
Infectious disease (3103)
Inflammatory bowel disease (217)
Inflation Reduction Act (14)
Influenza (137)
Intellectual property (301)
Interviews (320)
IPO (16674)
IRA (50)
Job creations (3649)
Job search strategy (1431)
JPM (58)
Kidney cancer (20)
Labor market (107)
Layoffs (568)
Leadership (40)
Legal (7955)
Liver cancer (103)
Longevity (33)
Lung cancer (815)
Lymphoma (448)
Machine learning (60)
Management (59)
Manufacturing (1086)
MASH (201)
Medical device (13954)
Medtech (14093)
Mergers & acquisitions (20201)
Metabolic disorders (1556)
mRNA (217)
Multiple sclerosis (193)
NASH (17)
Neurodegenerative disease (435)
Neuropsychiatric disorders (106)
Neuroscience (3374)
Neurotech (1)
NextGen: Class of 2026 (6522)
Non-profit (4536)
Now hiring (79)
Obesity (720)
Opinion (289)
Ovarian cancer (233)
Pain (258)
Pancreatic cancer (326)
Parkinson's disease (377)
Partnered (33)
Patents (610)
Patient recruitment (696)
Peanut (64)
People (59736)
Pharmaceutical (58)
Pharmacy benefit managers (33)
Phase 1 (22225)
Phase 2 (31380)
Phase 3 (23336)
Pipeline (9279)
Policy (322)
Postmarket research (2569)
Preclinical (9451)
Press Release (64)
Prostate cancer (322)
Psychedelics (54)
Radiopharmaceuticals (337)
Rare diseases (1107)
Real estate (5973)
Recruiting (70)
Regulatory (25574)
Reports (56)
Research institute (2418)
Resumes & cover letters (354)
Rett syndrome (39)
RNA editing (23)
RSV (88)
Schizophrenia (179)
Series A (297)
Series B (217)
Service/supplier (11)
Sickle cell disease (117)
Special edition (24)
Spinal muscular atrophy (167)
Sponsored (48)
Startups (3647)
State (2)
Stomach cancer (18)
Supply chain (130)
Tariffs (87)
The Weekly (64)
Vaccines (1123)
Venture capital (114)
Weight loss (460)
Women's health (130)
Worklife (20)
Date
Today (152)
Last 7 days (756)
Last 30 days (3365)
Last 365 days (30279)
2026 (14326)
2025 (30184)
2024 (35227)
2023 (40085)
2022 (51196)
2021 (55728)
2020 (54092)
2019 (46548)
2018 (35030)
2017 (32129)
2016 (31509)
2015 (37573)
2014 (31339)
2013 (26354)
2012 (28579)
2011 (29272)
2010 (27330)
Location
Africa (741)
Alabama (93)
Alaska (7)
Arizona (354)
Arkansas (14)
Asia (39823)
Australia (6552)
California (13652)
Canada (3854)
China (1414)
Colorado (580)
Connecticut (597)
Delaware (421)
Europe (86240)
Florida (2039)
Georgia (438)
Hawaii (3)
Idaho (63)
Illinois (1101)
India (92)
Indiana (617)
Iowa (23)
Japan (560)
Kansas (132)
Kentucky (50)
Louisiana (44)
Maine (76)
Maryland (1637)
Massachusetts (9753)
Michigan (370)
Minnesota (738)
Mississippi (6)
Missouri (146)
Montana (36)
Nebraska (29)
Nevada (145)
New Hampshire (84)
New Jersey (3573)
New Mexico (30)
New York (3574)
North Carolina (1723)
North Dakota (9)
Northern California (6871)
Ohio (408)
Oklahoma (23)
Oregon (41)
Pennsylvania (2736)
Puerto Rico (29)
Rhode Island (51)
South America (1112)
South Carolina (86)
South Dakota (2)
Southern California (5401)
Tennessee (216)
Texas (2171)
United States (48109)
Utah (405)
Vermont (1)
Virginia (329)
Washington D.C. (81)
Washington State (1090)
West Virginia (4)
Wisconsin (129)
Wyoming (2)
732,869 Results for "immunotherapeutics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
OSE Immunotherapeutics to Implement a Flexible Bridge Equity Financing
May 28, 2026
·
14 min read
Press Releases
OSE Immunotherapeutics Evolves its Leadership Team
April 15, 2026
·
5 min read
Press Releases
OSE Immunotherapeutics Reports Positive Topline Results of TEDOVA Phase 2 Trial with Tedopi® in Recurrent Ovarian Cancer
May 22, 2026
·
6 min read
Press Releases
OSE Immunotherapeutics Announces its 2026 Financial Calendar
March 16, 2026
·
3 min read
Press Releases
OSE Immunotherapeutics Reports Full Year 2025 Audited Consolidated Financial Results and Announces the Filing of its 2025 Universal Registration Document
June 4, 2026
·
6 min read
Press Releases
OSE Immunotherapeutics to Present at Upcoming Investor Conferences - March 23, 2026
March 24, 2026
·
3 min read
Press Releases
OSE Immunotherapeutics Reports Full Year 2025 Unaudited Consolidated Financial Results and 2026 Q1 Cash Position
April 30, 2026
·
9 min read
Press Releases
OSE Immunotherapeutics Welcomes FDA Orphan Drug Designation Granted to Pegrizeprument (VEL-101) for Prevention of Organ Rejection in Heart Transplant Patients
April 27, 2026
·
4 min read
Press Releases
OSE Immunotherapeutics Announces Presentation of TEDOVA Phase 2 Topline Results of Tedopi® in Ovarian Cancer at the ASCO 2026 Meeting
April 23, 2026
·
5 min read
Press Releases
OSE Immunotherapeutics Accelerates Strategic Refocusing to Advance Late Stage Value Drivers Lusvertikimab and Tedopi®
March 3, 2026
·
6 min read
1 of 73,287
Next
